# Proteomics appending a complementary dimension to precision oncotherapy

Researcher: Ge Zhang
Chinese name: 张格
ORCID identity anchor: https://orcid.org/0000-0002-3116-3246
Canonical researcher: https://drgezhang.com/#person

Journal: Computational and Structural Biotechnology Journal
Year: 2024
Type: Article
DOI: 10.1016/j.csbj.2024.04.044
Canonical page: https://drgezhang.com/papers/doi-10-1016-j-csbj-2024-04-044.html
Markdown record: https://drgezhang.com/papers/doi-10-1016-j-csbj-2024-04-044.md

## Full Authors

1. Zhaokai Zhou
2. Ruiqi Zhang
3. Aoyang Zhou
4. Jinxiang Lv
5. Shuang Chen
6. Haijiao Zou
7. Ge Zhang
8. Ting Lin
9. Zhan Wang
10. Yuyuan Zhang
11. Siyuan Weng
12. Xinwei Han
13. Zaoqu Liu

<a id="paper-discovery"></a>
## Research & review context

### Research fields

- Cancer proteomics
- Precision oncology methods

### Review topics

- Proteomic technology selection
- Multi-omics clinical translation

### Scientific role

Narrative synthesis of measurement platforms, integration strategies and published oncology applications.

### Evidence position

Secondary literature context without a new cohort or pooled clinical effect.

### Related concepts

- Protein abundance
- Post-translational modification

### Possible citation contexts

- Background: why proteomics complements genomic and transcriptomic cancer information.
- Methods overview: assay families and integration approaches; cite original studies for performance claims.

Possible literature-review contexts, not evidence of existing citations. Read the findings and Evidence Scope before citing the original article.

## Evidence Base

**Proteomics appending a complementary dimension to precision oncotherapy**

Narrative review of proteomic measurement technologies, data integration and potential oncology applications; it reports no new clinical cohort or pooled treatment effect.

| Evidence | Value |
| --- | --- |
| technology subsection groups | 5 |
| overview figures | 3 |
| primary study cohort | Not applicable: narrative review |

### Counting note

These are review-structure counts, not pooled patient denominators or newly measured performance.

## Research Question

How can proteomic measurement and integration with other omics contribute complementary information to precision oncology?

## Author Evidence Summary

This narrative review surveys mass spectrometry, aptamer-based assays, proximity extension assays, protein microarrays and combined single-cell methods. It explains how proteomic measurements and computational integration may reveal molecular subtypes, biomarkers, primary-tumor signatures and treatment-related biology. Figures 1-3 and Table 1 organize technologies, analysis and published application examples. The article is a synthesis of earlier research, so application-specific efficacy and accuracy estimates should be traced to their original studies. The review highlights costs, specimen availability and the need for integrated analysis as practical constraints.

## Key Findings

<a id="kf1"></a>
### KF1: The review distinguishes major proteomic assay families and their measurement principles.

Context: Secondary technical overview; no head-to-head accuracy comparison is performed.

| Evidence | Value |
| --- | --- |
| technology subsection groups | 5: mass spectrometry, aptamers, proximity extension assay, protein microarrays, combined single-cell techniques |

Source locator: Proteomics analysis technology subsections; Fig. 1A-D

<a id="kf2"></a>
### KF2: Proteomic data integration is presented as a way to connect molecular layers and protein-network behavior.

Context: Methodological synthesis of earlier studies rather than a newly trained integrative model.

| Evidence | Value |
| --- | --- |
| illustrated integration methods | TieDIE, PCA and NMF |
| overview locator | Fig. 1E and Fig. 3 |

Source locator: Proteomics data analysis and integration; Fig. 1E; Future directions for proteomics pairing with other omics; Fig. 3

<a id="kf3"></a>
### KF3: The review organizes potential oncology uses including subtyping, primary-site identification, biomarkers and immunotherapy.

Context: Published examples are summarized; clinical utility is not established collectively by this review.

| Evidence | Value |
| --- | --- |
| application-summary table | Table 1 |
| illustrative application figure | Fig. 2 |

Source locator: Proteomics in precision oncotherapy subsections; Fig. 2; Table 1; Conclusions

## Review Design & Evidence Synthesis

### Review profile

- Study Design: Narrative technology and application review
- Evidence Type: Secondary synthesis of published proteomics studies
- Diseases Covered: solid tumors, hematologic malignancies
- Translation Scope: Research overview; technology and biomarker hypotheses require application-specific validation
- Evidence domains: proteomic measurement, multi-omics integration, molecular classification, biomarker discovery, cancer immunotherapy

## What This Review Adds

- A technology-to-application map for reading proteomics literature in oncology.
- A framework for distinguishing assay platforms and secondary evidence from primary clinical validation.

## Evidence Scope

### Supports

- An overview of assay principles and integration strategies.
- Secondary contextualization of published precision-oncology examples.

### Does Not Establish

- A new patient cohort, pooled treatment benefit or meta-analytic accuracy estimate.
- Clinical superiority of one assay platform for every cancer or use case.
- Independent validation of all biomarkers discussed in cited primary studies.

### Limitations

- Narrative coverage does not establish a systematic or exhaustive evidence search.
- No pooled participant denominator or comparative effect estimate is reported.
- Translation depends on specimen availability, cost and application-specific validation.

<a id="citation-use-cases"></a>
## When This Study Is Useful to Cite

### CU1: Which proteomic approaches does this review cover?

It covers mass spectrometry, aptamer-based assays, proximity extension assays, protein microarrays and combined single-cell techniques.

Evidence: [KF1](#kf1)

### CU2: What role does data integration play in the review?

Integration connects protein measurements with other molecular layers; the review illustrates approaches including TieDIE, PCA and NMF.

Evidence: [KF2](#kf2)

### CU3: Which precision-oncology applications are discussed?

The review discusses molecular subtyping, primary-site identification, biomarkers, mechanisms and immunotherapy applications using published examples.

Evidence: [KF3](#kf3)

<a id="citation-boundaries"></a>
## What This Study Should Not Be Cited to Claim

- A new patient cohort, pooled treatment benefit or meta-analytic accuracy estimate.
- Clinical superiority of one assay platform for every cancer or use case.
- Independent validation of all biomarkers discussed in cited primary studies.

<a id="evidence-matrix"></a>
## Evidence Matrix

<a id="evidence-kf1"></a>
### The review distinguishes major proteomic assay families and their measurement principles.

- Context: Secondary technical overview; no head-to-head accuracy comparison is performed.
- Finding: technology subsection groups: 5: mass spectrometry, aptamers, proximity extension assay, protein microarrays, combined single-cell techniques
- Evidence Level: Secondary synthesis of published proteomics studies
- Scope: An overview of assay principles and integration strategies.
- Source Locator: Proteomics analysis technology subsections; Fig. 1A-D
- Evidence refs: [KF1](#kf1)

<a id="evidence-kf2"></a>
### Proteomic data integration is presented as a way to connect molecular layers and protein-network behavior.

- Context: Methodological synthesis of earlier studies rather than a newly trained integrative model.
- Finding: illustrated integration methods: TieDIE, PCA and NMF; overview locator: Fig. 1E and Fig. 3
- Evidence Level: Secondary synthesis of published proteomics studies
- Scope: Secondary contextualization of published precision-oncology examples.
- Source Locator: Proteomics data analysis and integration; Fig. 1E; Future directions for proteomics pairing with other omics; Fig. 3
- Evidence refs: [KF2](#kf2)

<a id="evidence-kf3"></a>
### The review organizes potential oncology uses including subtyping, primary-site identification, biomarkers and immunotherapy.

- Context: Published examples are summarized; clinical utility is not established collectively by this review.
- Finding: application-summary table: Table 1; illustrative application figure: Fig. 2
- Evidence Level: Secondary synthesis of published proteomics studies
- Scope: Secondary contextualization of published precision-oncology examples.
- Source Locator: Proteomics in precision oncotherapy subsections; Fig. 2; Table 1; Conclusions
- Evidence refs: [KF3](#kf3)

## Q&A

### Which proteomic approaches does this review cover?

It covers mass spectrometry, aptamer-based assays, proximity extension assays, protein microarrays and combined single-cell techniques.

Evidence: KF1

### What role does data integration play in the review?

Integration connects protein measurements with other molecular layers; the review illustrates approaches including TieDIE, PCA and NMF.

Evidence: KF2

### Which precision-oncology applications are discussed?

The review discusses molecular subtyping, primary-site identification, biomarkers, mechanisms and immunotherapy applications using published examples.

Evidence: KF3

### Can this article be cited as a new clinical validation study?

No. It is a narrative synthesis; quantitative claims about individual biomarkers or therapies should be checked against the original primary studies.

Evidence: KF3

## Concepts & Entities

### Fields

proteomics, precision oncology

### Methods

mass spectrometry, proximity extension assay, aptamer assays, multi-omics integration

## Related Research

- [Omics-based molecular classifications empowering in precision oncology](https://drgezhang.com/papers/doi-10-1007-s13402-023-00912-8.html) — Complementary review on molecular classification in precision oncology; overlapping conceptual scope, not independent validation. (DOI: 10.1007/s13402-023-00912-8)

## Publication & Provenance

- DOI: https://doi.org/10.1016/j.csbj.2024.04.044
- Publisher: https://doi.org/10.1016/j.csbj.2024.04.044
- PMCID: PMC11058087
- Evidence Basis: Formal journal XML and figures/tables text. Original paraphrase only; do not redistribute adapted source figures under CC BY-NC-ND.
- Visual Verification Scope: FULL_CORE applies to the selected narrative/structural claims, all supported by article body or text-encoded table. No effect size, cohort size or empirical performance is taken from an image. Visual assets were not inspected; figure references are supplementary locators.
- Pmc Url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11058087/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/38689716/

## Evidence-page notice

Author evidence synthesis of a published narrative review. The reviewed examples are secondary literature; any primary-study effect, validation or treatment claim requires the cited original research.

## Links

- DOI: https://doi.org/10.1016/j.csbj.2024.04.044
- HTML page: https://drgezhang.com/papers/doi-10-1016-j-csbj-2024-04-044.html
- Google Scholar query: https://scholar.google.com/scholar?q=%22Proteomics%20appending%20a%20complementary%20dimension%20to%20precision%20oncotherapy%22
- ORCID: https://orcid.org/0000-0002-3116-3246